Tarsus anticipates late 2023 launch of Demodex therapy, expansion into MGD, Lyme, rosacea
NEW YORK — A Tarsus executive said the company is looking forward to FDA approval of TP-03, a 0.25% lotilaner ophthalmic solution for treatment of Demodex blepharitis, in late summer 2023.